BACKGROUND As a result of the COVID-19 pandemic, institutions needed innovative solutions to provide care. With implementation of telehealth, the cystic fibrosis pharmacist was able to incorporate a virtual medication tour during appointments. OBJECTIVE The purpose of our study was to describe the uptake and impact of pharmacist-led virtual medication tours during telehealth visits in the CF clinic setting. PRACTICE DESCRIPTION Prior to the COVID-19 pandemic, the cystic fibrosis pharmacist participated in in-person multidisciplinary team visits to complete medication history reconciliation, assess adherence, assess efficacy and address possible side effects of medications, and work collaboratively with the CF care team and patient to create therapeutic plans. The virtual medication tour described in this study was completed in addition or as a complement to these pre-existing pharmacist roles and responsibilities. PRACTICE INNOVATION Patients seen via telehealth visit were asked to provide a virtual tour of their medications. The pharmacist completed medication history and evaluated whether or not storage conditions were appropriate in regards to temperature, humidity, light exposure, and accessibility to children. EVALUATION METHODS The pharmacist recorded findings from the virtual medication tours, and made interventions when appropriate. Descriptive statistics were used for analysis. RESULTS Of 20 patients seen via telehealth for a quarterly visit during the first 3 months after implementation, 13 were willing to participate in a virtual medication tour. Prior to the visit, 25% had information missing from their medication list. Virtual medication tour allowed for resolution of this information 80% of the time. Three of the four participating patients with a child under 12 years old had medications stored in a location accessible to children. PRACTICE IMPLICATIONS AND CONCLUSION A virtual medication tour led by a pharmacist can be successfully incorporated into telehealth visits, and was accepted by a majority of patients. Most patients stored medications appropriately, but might benefit from education on poison prevention practices.

ImportancePeople who survive hospitalization for COVID-19 are at risk for developing new cardiovascular, neurological, mental health, and inflammatory autoimmune conditions. It is unclear how posthospitalization risks for COVID-19 compare with those for other serious infectious illnesses.ObjectiveTo compare risks of incident cardiovascular, neurological, and mental health conditions and rheumatoid arthritis in 1 year following COVID-19 hospitalization against 3 comparator groups: prepandemic hospitalization for influenza and hospitalization for sepsis before and during the COVID-19 pandemic.Design, Setting, and ParticipantsThis population-based cohort study included all adults hospitalized for COVID-19 between April 1, 2020, and October 31, 2021, historical comparator groups of people hospitalized for influenza or sepsis, and a contemporary comparator group of people hospitalized for sepsis in Ontario, Canada.ExposureHospitalization for COVID-19, influenza, or sepsis.Main Outcome and MeasuresNew occurrence of 13 prespecified conditions, including cardiovascular, neurological, and mental health conditions and rheumatoid arthritis, within 1 year of hospitalization.ResultsOf 379 366 included adults (median [IQR] age, 75 [63-85] years; 54% female), there were 26 499 people who survived hospitalization for COVID-19, 299 989 historical controls (17 516 for influenza and 282 473 for sepsis), and 52 878 contemporary controls hospitalized for sepsis. Hospitalization for COVID-19 was associated with an increased 1-year risk of venous thromboembolic disease compared with influenza (adjusted hazard ratio, 1.77; 95% CI, 1.36-2.31) but with no increased risks of developing selected ischemic and nonischemic cerebrovascular and cardiovascular disorders, neurological disorders, rheumatoid arthritis, or mental health conditions compared with influenza or sepsis cohorts.Conclusions and RelevanceIn this cohort study, apart from an elevated risk of venous thromboembolism within 1 year, the burden of postacute medical and mental health conditions among those who survived hospitalization for COVID-19 was comparable with other acute infectious illnesses. This suggests that many of the postacute consequences of COVID-19 may be related to the severity of infectious illness necessitating hospitalization rather than being direct consequences of infection with SARS-CoV-2.